October 2026 · 7 min read
Kisspeptin-10: what the human neuroendocrine literature measured
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
Kisspeptin is unusual in this catalogue: it is a compound whose research literature is real, current, human and conducted by identifiable academic groups, and whose marketing claims are mostly borrowed from somewhere else entirely. The useful reading of the papers is also the narrow one. They measure hormones in blood samples.
The genetics came first, and that is why the field exists
In 2003, two groups independently reported that loss-of-function mutations in the receptor then called GPR54 cause hypogonadotropic hypogonadism — a failure to enter puberty. de Roux and colleagues published in PNAS (PMID 12944565) and Seminara and colleagues in the New England Journal of Medicine (PMID 14573733).
That is a strong result of a kind the rest of this catalogue rarely has: human genetics established that signalling through this receptor is required for normal reproductive development, before anybody administered anything to anyone. Every human study since has been built on it. The receptor was renamed KISS1R, and its ligand is the product of the KISS1 gene — which also carries the older name metastin, from work on metastasis suppression that preceded the reproductive findings.
Kisspeptin-10 is not kisspeptin-54, and this matters
The KISS1 gene encodes a precursor that is cleaved into peptides of several lengths. Kisspeptin-54 is the longer form. Kisspeptin-10 is the C-terminal decapeptide — the minimal fragment that retains receptor binding, which is why it exists as a reagent at all. This catalogue also lists its synonym metastin 45-54, which simply states which residues of the precursor it is.
The two behave differently in circulation. Kisspeptin-10 clears faster, which is the main reason the longer form was preferred in the early human experiments. So the mapping between studies and the vial is not clean:
| Study | Form used | What it measured |
|---|---|---|
| Dhillo 2005, men (PMID 16174713) | Kisspeptin-54 | LH, FSH, testosterone |
| Dhillo 2007, women (PMID 17635940) | Kisspeptin-54 | Gonadotropin release across the menstrual cycle |
| Jayasena 2009 (PMID 19820030) | Kisspeptin-54 | Gonadotropins, and loss of response on continued exposure |
| George 2011, men (PMID 21632807) | Kisspeptin-10 | LH concentration and LH pulse frequency |
| Yeung 2026, men (PMID 42549827) | Kisspeptin-10 | Gonadotropin secretion over twelve days |
A finding obtained with kisspeptin-54 is not a finding about kisspeptin-10. The two overlap in receptor pharmacology and differ in exposure, and papers that use one should not be cited for the other.
Who did the work
Most of the human literature traces to Waljit Dhillo's group at Imperial College London, working out of the department Stephen Bloom built, with collaborators including Channa Jayasena and Ali Abbara. As with BPC-157 and Zagreb, one centre producing the large majority of a compound's human data is not disqualifying, but it is the first thing to know: the methods and assumptions are shared across the set, and independent replication is thinner than the citation count suggests.
The 2025 Physiological Reviews survey by Koysombat and colleagues covers kisspeptin and neurokinin B in reproductive physiology (PMID 39813600), and is the right starting point for reading seriously.
What the studies examined
Position in the axis. Kisspeptin acts upstream of gonadotropin-releasing hormone, on GnRH neurones in the hypothalamus, rather than on the pituitary directly. That makes it a tool for asking when and how the axis is switched on, which is a different question from stimulating it.
Gonadotropin secretion in healthy volunteers. The endpoints are luteinising hormone and follicle-stimulating hormone concentrations in blood, sometimes with pulse frequency derived from frequent sampling. George and colleagues reported effects on both measures in men using kisspeptin-10 (PMID 21632807).
Desensitisation. Jayasena and colleagues reported that continued exposure produced tachyphylaxis — the response falling away rather than persisting (PMID 19820030). This is the single most important limit in the file, because it bounds what any sustained use of a KISS1R agonist could do, and it is in the title of the paper.
Puberty-timing models. The larger half of the literature by volume is animal work using kisspeptin as a tool for probing when the reproductive axis switches on during development. A tool for asking a question in an animal is not a finding about a person, and that is the correct weight to give it.
Oocyte maturation in IVF. Kisspeptin has been examined as a trigger of oocyte maturation, the clinical question with the clearest route to an indication (PMID 36147569). The programme that followed uses MVT-602, a longer-acting KISS1R agonist studied in randomised placebo-controlled work in premenopausal women (PMID 37925096) — a different molecule from the decapeptide sold here.
Where the evidence stops
Hormones in blood are not clinical outcomes. A rise in LH is a physiological measurement. Reading it as a result about fertility, mood or anything else is the step the papers do not take.
The studies are small and short. Tens of participants, hours to days, healthy volunteers or a single patient group.
No phase 3 programme has reported for kisspeptin-10. The industry development that exists is for an analogue.
It is approved nowhere. Not by Health Canada, not by the FDA, not by the EMA, for any indication, in any jurisdiction. It is investigational research material and nothing else.
For another hypothalamic-pituitary research tool whose literature is about selectivity rather than outcome, see Ipamorelin, ageing and somatopause. For a compound where an approved medicine and a research chemical are easiest to confuse, see PT-141 and the melanocortin receptors. For a peptide whose name promises what its literature never delivered, see DSIP and sleep. Nothing here is medical, dosing, or therapeutic guidance.
Kisspeptin-10 is supplied here as Kisspeptin-10. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.
Common questions
Is kisspeptin-10 a fertility treatment? No. It is not approved anywhere for anything. Kisspeptin has been examined as an oocyte-maturation trigger in IVF research, and the compound carried furthest in that direction is an analogue rather than this decapeptide.
Why is the human literature better than for most research peptides? Because the genetics came first. A receptor shown by human mutation studies to be required for puberty is a target worth funding, and the resulting studies were run in university hospitals with endocrine assays and ethics approval.
What does the tachyphylaxis finding mean? That the acute and the sustained response are different questions, and only the acute one is well characterised. Any claim built on continuous exposure runs into a published result pointing the other way.
Is it legal to buy in Canada? It is sold here as a research chemical, for laboratory use only. It is not an approved drug in Canada and is not sold for human use.
Selected Research References
- de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic Hypogonadism Due to Loss of Function of the KiSS1-Derived Peptide Receptor GPR54. Proceedings of the National Academy of Sciences. 2003;100(19):10972-10976. pubmed.ncbi.nlm.nih.gov/12944565
- Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 Gene as a Regulator of Puberty. New England Journal of Medicine. 2003;349(17):1614-1627. pubmed.ncbi.nlm.nih.gov/14573733
- Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 Stimulates the Hypothalamic-Pituitary Gonadal Axis in Human Males. Journal of Clinical Endocrinology & Metabolism. 2005;90(12):6609-6615. pubmed.ncbi.nlm.nih.gov/16174713
- Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 Stimulates Gonadotropin Release Most Potently During the Preovulatory Phase of the Menstrual Cycle in Women. Journal of Clinical Endocrinology & Metabolism. 2007;92(10):3958-3966. pubmed.ncbi.nlm.nih.gov/17635940
- Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous Injection of Kisspeptin-54 Acutely Stimulates Gonadotropin Secretion in Women with Hypothalamic Amenorrhea, but Chronic Administration Causes Tachyphylaxis. Journal of Clinical Endocrinology & Metabolism. 2009;94(11):4315-4323. pubmed.ncbi.nlm.nih.gov/19820030
- George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. Journal of Clinical Endocrinology & Metabolism. 2011;96(8):E1228-E1236. pubmed.ncbi.nlm.nih.gov/21632807
- Sharma B, Koysombat K, Comninos AN, Dhillo WS, Abbara A. Use of Kisspeptin to Trigger Oocyte Maturation During In Vitro Fertilisation (IVF) Treatment. Frontiers in Endocrinology. 2022;13:972137. pubmed.ncbi.nlm.nih.gov/36147569
- Abbara A, Ufer M, Voors-Pette C, et al. Endocrine Profile of the Kisspeptin Receptor Agonist MVT-602 in Healthy Premenopausal Women With and Without Ovarian Stimulation. Fertility and Sterility. 2024;121(1):95-106. pubmed.ncbi.nlm.nih.gov/37925096
- Koysombat K, Tsoutsouki J, Patel AH, Comninos AN, Dhillo WS, Abbara A. Kisspeptin and Neurokinin B: Roles in Reproductive Health. Physiological Reviews. 2025;105(2):707-764. pubmed.ncbi.nlm.nih.gov/39813600
- Yeung AC, Phylactou M, Koysombat K, et al. Chronic Subcutaneous Kisspeptin-10 Stimulates Gonadotropin Secretion for 12 Days in Healthy Men. European Journal of Endocrinology. 2026;195(2):206-216. pubmed.ncbi.nlm.nih.gov/42549827
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.